Current Meeting     Our Mission     Future & Past Programs      Sponsorship     Board of Directors     Contact Us
Meeting Announcement
Date: Wednesday, April 26th, 2017
Topic: "The Right Medicine for the Right Patient - Challenges and Opportunities of Precision Medicine"
Speaker: Dietmar Berger, M.D., Ph.D.
Senior Vice President, Global Head of Clinical Development for Hematology/Oncology Product Development

The Holiday Inn
275 S Airport Blvd
South San Francisco, CA 94080
650-873-3550 | Map
Next door to the SSF Conference Center
Directions at


$50 before 9PM, Monday, April 24th
$60 on-site
$40 full-time students pre-registration
$50 full-time students on-site
$3 service fee will be added to the pre-registration price

6:00 PM - networking
7:00 PM - dinner
8:00 PM - presentation

Gold Sponsors

Fisher Clinical
ReImagine Science
RHS Financial

Silver Sponsors


Location Sponsor



Oncology has changed dramatically over recent years - a deeper understanding of tumor drivers, cancer biology and immunology has led to a plethora of new treatment approaches, including targeted molecules and cancer immunotherapies. State of the art diagnostics predict efficacy of treatments across cancer types and independent of "standard" tumor classifications by tissue of origin. In the future, the confluence of cutting-edge medicines, comprehensive diagnostics and genomic sequencing, and the application of new technologies and data sources (including real-world data) will lead to an even more personalized paradigm. These developments pose both opportunities and challenges from a pharmaceutical and biotechnology perspective.

Dr. Dietmar Berger will speak about Genentech's approach to this changing oncology landscape, including development of novel targeted therapies, integration of diagnostic platforms, and personalized cancer immunotherapy. Novel trial designs and rapid application of new biomarker insights have led to accelerated pathways for clinical testing and regulatory submissions. Dr. Berger will also discuss the mechanism of action of selected immunotherapy and small molecule products in the clinic and the progress of selected clinical candidates in solid tumors and hematology.


Dietmar Berger is Senior Vice President and Global Head, Product Development, Clinical Hematology and Oncology at Roche/Genentech. In this role, Dr. Berger leads the medical strategy for the company's global clinical development portfolio for cancer medicines. Dr. Berger was formerly Vice President of Global Clinical Development for Roche/Genentech's HER2 breast cancer franchise and was instrumental in the development and marketing approvals of two breast cancer medicines across three new indications.

Dr. Berger has more than 20 years of experience in oncology research and development, including as Head of the Clinical Research Center at the University Medical Hospital, Freiburg, Germany. He has held leadership positions at several global pharmaceutical companies and also received the Cancer Award of the German Cancer Society for his research on angiogenesis. Dr. Berger has authored more than 40 scientific publications and five books.

Registration Policy    Registration via CEvent     Map